Quest Diagnostics Q4 Revenue Climbs 7.1%, EPS Rises 11.8%, Dividend Increased
Quest Diagnostics posted Q4 revenues of $2.81B (+7.1%) and diluted EPS of $2.18 (+11.8%), while full-year revenues reached $11.04B (+11.8%) with reported EPS of $8.75 (+13.8%). The company raised its quarterly dividend by 7.5% to $0.86 and forecasts 2026 revenues of $11.70–11.82B with EPS of $9.45–9.65.
1. Financial Results for Q4 and Full Year 2025
Quest Diagnostics reported Q4 net revenues of $2.806 billion, up 7.1% year-over-year, with diluted EPS of $2.18 (up 11.8%) and adjusted EPS of $2.42 (up 8.5%). For the full year, revenues rose 11.8% to $11.04 billion, reported EPS increased 13.8% to $8.75, adjusted EPS climbed 10.3% to $9.85, and cash from operations reached $1.89 billion.
2. 2026 Revenue and EPS Guidance and Dividend Hike
Management projected 2026 revenues between $11.70 billion and $11.82 billion, with reported diluted EPS of $9.45–9.65 and adjusted EPS of $10.50–10.70. The quarterly dividend was raised by 7.5% to $0.86 per share, reflecting confidence in cash flow stability and shareholder returns.
3. Strategic Collaborations and Market Expansion
Key strategic moves include a major Co-Lab Solutions deployment and laboratory joint venture with Corewell Health in Michigan, scaled diagnostics services for over 200,000 dialysis patients at Fresenius, integration of eight acquisitions to enter Canada, and new partnerships with Epic for order-to-cash transformation and consumer wellness platforms.
4. Operational Excellence and Technology Investments
Quest Diagnostics achieved 3% annual cost savings through its Invigorate program and deployed AI, automation, and Google Cloud generative AI across lab and administrative systems to boost productivity and data analytics. Recent clinical innovations include a Quest AD-Detect® Alzheimer’s test, long-read gene sequencing, and FDA breakthrough designation for the Haystack MRD® cancer monitoring test.